Comorbidity Measures for Use with Administrative Data

Anne Elixhauser, Claudia Steiner, D.R. Harris, +1

Medical Care

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

Benjamin Diop-Frimpong, Vikash P. Chauhan, Stephen M. Krane, +2

Proceedings of the National Academy of Sciences

NanotherapeuticsEngineeringTumor BiologyHuman BreastNanomedicine +15

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

Anthony F. Lever, David Hole, C. Gillis, +7

The Lancet

Inhibitory ActivityOncologyMedicinePathologyPharmacotherapy +6

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

Janet E. Murphy, Jennifer Y. Wo, David P. Ryan, +28

JAMA Oncology

Pancreatic cancer: why is it so hard to treat?

Paul E. Oberstein, Kenneth P. Olive

Therapeutic Advances in Gastroenterology

Tumor BiologySurgical OncologyPancreatic CancerMedicineImmunology +9

Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways

Radia Tamarat, Jean‐Sébastien Silvestre, Micheline Durie, +1

Laboratory Investigation

InflammationHypertensionAngiogenesisCardiovascular DiseaseMedicine +12

Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

Yousuke Nakai, Hiroyuki Isayama, Hideaki Ijichi, +17

British Journal of Cancer

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

Stefan Wilop, Sabine von Hobe, Martina Crysandt, +3

Journal of Cancer Research and Clinical Oncology

MedicinePharmacologyBronchial NeoplasmImmune Checkpoint InhibitorPharmacotherapy +6

Angiotensin-converting enzyme inhibitors and the risk of cancer

S. Friis, Henrik Toft Sørensen, Lene Mellemkj�r, +4

Cancer

Antihypertensives as Novel Antineoplastics: Angiotensin-I-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Pancreatic Ductal Adenocarcinoma

Hwyda A. Arafat, Qiaoke Gong, Galina Chipitsyna, +3

Journal of the American College of Surgeons